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The purpose of this prospective studywas to investigate whether
correlations exist between 18F-FDG uptake of primary breast
cancer lesions and predictive and prognostic factors such as es-
trogen receptor (ER), progesterone receptor (PR), and C-erbB-2
receptor (C-erbB-2R) states. Methods: Before undergoing par-
tial or total mastectomy, 213 patients with newly diagnosed
breast cancer underwent 18F-FDG PET (5.2 MBq/kg of body
weight). The maximum standardized uptake value (SUV) of the
primary lesion wasmeasured in each patient. Standard immuno-
histochemistry was performed on a surgical specimen of the
cancer lesion to characterize the receptor state of the tumor
cells. Pearson x2 tests were performed on the cross-tables of dif-
ferent receptor states to test any association that may exist
among ER, PR, and C-erbB-2R. Maximum SUV measurements
for different receptor states were compared using factorial
ANOVA in a completely random design. Results: After exclusion
of certain lesions, 118 lesions were analyzed for this study. The
mean maximum SUVs of ER-positive and ER-negative lesions
were 3.03 6 0.26 and 5.64 6 0.75, whereas those of PR
were 3.24 6 0.29 and 4.89 6 0.67, respectively, and those of
C-erbB-2R were 4.64 6 0.70 and 3.70 6 0.35, respectively. x2
tests for ER and PR showed that if one is positive then the other
tends to be positive as well (x2 5 71.054, P , 0.01). For ER and
C-erbB-2R states, if ER is positive, C-erbB-2R will more likely
be negative (x25 13.026,P, 0.01). No relationshipwas detected
between PR and C-erbB-2R states (x2 5 3.695, P . 0.05).
ANOVAs showed that PR state alone (F 5 0.095, P . 0.05) and
C-erbB-2R state alone (F 5 0.097, P . 0.05) had no effect on
18F-FDG uptake but ER state alone had an effect (F 5 9.126, P ,
0.01). ER and PR being together had no additional effect on 18F-
FDG uptake. Our study also demonstrated that interactions exist
between ER and C-erbB-2R state and between PR and C-erbB-
2R state. Conclusion: SUV measurements may provide valuable
information about the state of ER, PR, and C-erbB-2R and the as-
sociated glucose metabolism as measured by 18F-FDG uptake of
the primary breast cancer lesions. Such an association may be of
importance to treatment planning and outcome in these patients.
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PET, using the radiolabeled glucose analog 18F-FDG,
can detect enhanced glycolysis of cancer cells and has been
proven valuable in diagnosing, staging, detecting recur-
rences, and assessing response to therapy in a multitude
of malignant disorders (1). 18F-FDG PET is a noninvasive
diagnostic modality that also provides quantitative data on
the level of metabolic activity by calculating the degree
of 18F-FDG uptake, known as standardized uptake value
(SUV). Breast cancer is the most common cancer among
women, with an increasing prevalence (2), and is curable
with early diagnosis and optimal treatment. Among various
tests for predicting response to treatment, determination of
estrogen receptor (ER) and progesterone receptor (PR) in
tumor cells is essential for appropriate hormone therapy.
The C-erbB-2 (also known as HER-2 [human epidermal
growth factor receptor-2] or neu) receptor (C-erbB-2R) has
recently been introduced as another predictive and prog-
nostic marker for this malignancy. Determination of this
receptor is useful for selecting patients with advanced
breast cancer for treatment with therapeutic antibodies such
as trastuzumab (Herceptin; Genentech) (3).
Breast carcinomas appear to display considerable vari-
ability with regard to 18F-FDG uptake, resulting in reports
of a wide range of sensitivity and specificity values that,
in turn, have brought its diagnostic utility into question
(4–11). Breast cancer lesions are noted to have character-
istically lower SUVs than other malignancies. Therefore,
tumor characteristics that may explain the underlying bio-
logic properties of glucose metabolism of the lesion and,
therefore, 18F-FDG accumulation would require further
investigation. Several studies have investigated the corre-
lation between 18F-FDG uptake and a variety of prognostic
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and molecular biomarkers for predicting tumor response to
therapy (9,12–15). Yet, based on published literature, no
correlation has been reported between 18F-FDG uptake and
the ER, PR, and C-erbB-2R states of malignant breast
cancer lesions. Thus, research studies determining factors
that govern uptake of 18F-FDG in proven breast lesions
would be of value in defining the role of this technique in
the management of patients with this cancer.
18F-FDG uptake in breast cancer usually indicates the
degree of tumor metabolism and hence can predict its
behavior and prognosis. On the other hand, the ER, PR,
and C-erbB-2R state of breast cancer is a biomarker that
provides important prognostic information in addition to
predicting response to therapy. The main objective of this
study was to determine whether a correlation exists between
18F-FDG uptake in untreated cases of breast cancer and their
ER, PR, and C-erbB-2R state. In addition, we also investi-
gated individual interactions among these receptors and how
they might influence the degree of 18F-FDG uptake in lesions.
MATERIALS AND METHODS
Patient Population
Two hundred thirteen consecutive patients (median age, 51 y;
range, 24–80 y) with biopsy-proven primary breast cancer who
were examined by film-screen mammography, ultrasound, MRI,
and 18F-FDG PET were enrolled in this prospective study. For the
purposes of this scientific communication, we present only data
that were generated with 18F-FDG PET. This prospective National
Institutes of Health–funded project was designed to test the role
of various imaging modalities for detecting and staging primary
breast cancer. This study complied with the Health Insurance
Portability and Accountability Act and was approved by the Insti-
tutional Review Board. Informed consent was obtained from all
patients. 18F-FDG PETwas performed after breast cancer had been
diagnosed through biopsy. The average (and SD) time between the
diagnostic biopsy and 18F-FDG PET was 24 6 13 d. None of the
patients had received chemotherapy or radiation therapy before
undergoing 18F-FDG PET for preoperative staging. After PET,
patients underwent a surgical intervention that included either
partial or total mastectomy for the primary lesion. Surgical pathol-
ogy results were considered to provide the definitive diagnosis
against which the PET study results were compared.
Imaging Procedure and Image Analysis
PET scans were obtained on a dedicated whole-body PET
scanner (Allegro; Philips Medical System). The patients fasted for
at least 4 h, and serum glucose levels were less than 140 mg/dL.
18F-FDG (5.2 MBq/kg of body weight) was administered intra-
venously through an indwelling catheter inserted into an antecubital
vein. The scan was obtained 60 min after the injection. Sequential
overlapping scans were obtained as a whole-body image that
included the entire trunk (from neck to groin). Transmission scans
using a 137Cs point source were interleaved between the multiple
emission scans to correct for nonuniform attenuation. The images
were reconstructed using an iterative reconstruction algorithm. Both
slice thickness and slice interval were 4 mm.
After image reconstruction, a region of interest was carefully
drawn around the site of the breast lesion on the consequent 4–6
PET scan slices. This analysis was performed uniformly by an
experienced nuclear medicine physician for the entire population
examined. From these ROIs, the maximum SUV (SUVmax)
was calculated by the inbuilt software of the PET scanner. The
SUVmax of 18F-FDG was measured from regions of interest
placed at the site of the lesion as clearly visualized on the PET
scan. We used only SUVmax for our analyses because the mean
SUV of the lesion is operator-dependent. The interpreting physi-
cian identified the breast lesions using the traditional and wide-
spread method of visual assessment.
Immunohistochemistry and Tissue Receptor Analysis
Immunohistochemical analyses were performed on the surgical
tissue specimen of the primary breast cancer lesion. The tumor tis-
sue was analyzed for ER, PR, and C-erbB-2R state using standard-
ized immunohistochemical techniques and robotic autostainers
(DakoCytomation, Inc.).
The ER state was evaluated using a monoclonal mouse anti-
human antibody directed against ERa (clone 1D5; DakoCytoma-
tion). PR state was assayed using a monoclonal mouse antihuman
antibody directed against the PR (clone PgR 636; DakoCytoma-
tion). Both procedures were performed on formalin-fixed paraffin-
embedded tissue using heat-induced epitope retrieval. Binding
results were visualized with the Envision1 system (DakoCytoma-
tion), which uses a horseradish peroxidase–labeled polymer that is
conjugated with secondary antibodies. Diaminobenzidine was used
as the chromogen (16,17). A visual scoring system was used for
interpretation and for estimating the percentage of nuclear labels in
the tumor cells. Tissues with less than 5% nuclear labeling were
considered negative. The tissue analysis for C-erbB-2R state was
done using the HercepTest (DakoCytomation), which uses a rabbit
antihuman C-erbB-2 protein on formalin-fixed paraffin-embedded
tissue using heat-induced epitope retrieval. Binding results were
visualized with a dextran polymer conjugated with horseradish
peroxidase and affinity-isolated goat antirabbit immunoglobulins.
Diaminobenzidine was used as the chromogen. A visual scoring
system was used for interpretation: 0 (no staining is observed or
membrane staining is observed in less than 10% of tumor cells),
11 (a faint, barely perceptible membrane staining is detected in
more than 10% of tumor cells; cells are stained in only part of their
membrane), 21 (a weak to moderate complete membrane staining
is observed in more than 10% of tumor cells), and 31 (a strong,
complete membrane staining is observed in more than 10% of
tumor cells). The results were scored on a scale of 0 to 31 using the
grading system approved by the United States Food and Drug
Administration. In this system (18) and in our study, cases scored as
either 0 or 11 were considered C-erbB-2R–negative (C-erbB-2R2)
and those with either 21 or 31 were considered C-erbB-2R–
positive (C-erbB-2R1).
Statistical Analysis
Pearson x2 tests were performed on the cross-tables of different
receptors to test any association among ER, PR, and C-erbB-2R
states. SUVmax measurements for different receptor states were
compared using factorial ANOVA in completely random designs.
Because of missing combinations, only 2-way ANOVA was per-
formed on all combinations of receptors. SPSS software (SPSS
Inc.) was used for all statistical analyses.
RESULTS
Among 213 patients with newly diagnosed breast cancer,
30 had undergone diagnostic excisional biopsy before
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18F-FDG PET, and therefore, no residual tumor was left in
the surgical specimen (all tumor tissue was removed dur-
ing diagnostic biopsy). Thirty-eight patients were noted to
have complications due to diagnostic excisional biopsy, in-
cluding seromas, hematomas, and significant inflammatory
reactions. No 18F-FDG uptake was detected in 31 patients,
and therefore, no abnormality was visualized on PET for
SUV analysis (false-negative). Among these 31 patients,
6 had tumors smaller than 5 mm. We excluded lesions
smaller than 5 mm. For the remaining so-called false-
negative results—25 lesions (10 noninvasive and 15 in-
vasive)—we could not calculate SUV because the lesions
had no increased 18F-FDG uptake and were invisible on
PET scans. Their SUVmax was as low as the background
and equal to that of normal glandular tissue. Therefore, we
did not include these lesions in the analyses. However, we
think that their receptor states are important. Among 25
malignant lesions, all ER-positive (ER1), 18 were PR-
positive (PR1) and only one was C-erbB-2R1. Thus, we
excluded a total of 99 patients from consideration for this
study. The remaining 114 patients with 118 malignant
breast tumors (4 patients had bilateral cancer), which were
clearly seen in the surgical specimen after 18F-FDG PET,
were considered appropriate for this analysis. We analyzed
118 (102 invasive and 16 noninvasive carcinoma in situ)
malignant lesions that had undergone 18F-FDG PET, and
the tumor was definable on the surgical specimen. The
lesion size of the 102 invasive malignant lesions ranged
from 5 to 60 mm. The subtypes of invasive malignant
lesions were as follows: 81 ductal, 8 lobular, 9 mixed
(ductal plus lobular), 3 tubular, and 1 medullary.
We performed Pearson x2 tests on the cross-tables of
different receptors to test for any association among ER,
PR, and C-erbB-2R. Between ER and PR states, it was
found that if one is positive the other tends to be positive as
well (x2 5 71.054, P , 0.01). If ER is positive, C-erbB2R
will likely be negative in the same lesion (x2 5 13.026, P
, 0.01). No correlation was detected between PR and
C-erbB-2R states in the tumors examined (x2 5 3.695,
P . 0.05).
18F-FDG PET detected all 118 surgically proven malig-
nant lesions larger than 5 mm. Among these, 82 were ER1,
36 ER-negative (ER2), 76 PR1, 42 PR-negative (PR2),
20 C-erbB-2R1, and 96 C-erbB-2R2. In 2 lesions, the
C-erbB-2R state could not be determined. The mean values
(and SD) of the SUVmax of ER1 and ER2 lesions were
3.03 6 0.26 and 5.64 6 0.75, whereas those of the PR
lesions were 3.24 6 0.29 and 4.89 6 0.67, respectively,
and those of the C-erbB-2R lesions were 4.64 6 0.71 and
3.70 6 0.35, respectively.
ANOVA showed that the SUVmax of the ER1 lesions
and the SUVmax of the ER2 lesions were significantly
different (F 5 9.126, P , 0.01). However, no significant
differences were found between the SUVs of the PR1 and
PR2 lesions (F5 0.095, P. 0.05) or the C-erbB-2R1 and
C-erbB-2R2 lesions (F 5 0.097, P . 0.05). PR or C-erbB-
2R states alone had no effect on 18F-FDG uptake, but the
ER state alone had an effect on 18F-FDG uptake. ER2
lesions had a significantly higher SUVmax than did ER1
lesions. In other words, statistical analysis demonstrated
that ER state affects SUV irrespective of PR state, and PR
state does not affect SUV irrespective of ER state. No
interaction was detected between ER and PR states, indi-
cating that the effects of ER and PR states on 18F-FDG
uptake were independent of each other. The effects of ER
and PR on 18F-FDG uptake are given in Tables 1 and 2 and
Figure 1A.
Two-way ANOVA of the ER and C-erbB-2R states
showed an interaction between the effects of these receptors
(Tables 3 and 4; Fig. 1B). When both these receptors are
either positive or negative, the SUVmax is higher than that
in lesions for which only one receptor is positive. A similar
interaction exists between PR state and C-erbB-2R state
(Tables 5 and 6; Fig. 1C). These interactions of C-erbB-2R
with ER and PR can be interpreted as indicating that the
presence or absence of C-erB-2R reverses the effects of
either PR or ER on SUVmax measurements.
DISCUSSION
Breast cancer is the second leading cause of death from
any malignancy among women (2). Although breast cancer
is curable when detected early, about one third of women
with breast cancer will die of the disease (19). Variable
factors have been considered important for predicting and
forecasting prognosis in these patients, including the state
of ER, PR, and C-erbB-2R in the excised tumor. The results
from these biologic measurements are of pivotal impor-
tance for the management of breast cancer patients. Mul-
tiple expert panels, including those of the American Society
of Clinical Oncology, the National Academy of Clinical
Biochemistry (United States), the National Institutes of
TABLE 1
SUVmax Means in Different States of PR and ER
ER
Negative Positive
PR n SUVmax SE n SUVmax SE
Negative 33 5.54 0.82 9 2.49 0.52
Positive 3 6.80 0.70 73 3.10 0.28
TABLE 2
ANOVA Table of PR and ER Effects on SUVmax
Source
Sum of
squares df
Mean
square F P
ER 93.408 1 93.408 9.126 0.003
PR 7.141 1 7.141 0.698 0.405
ER · PR 0.875 1 0.875 0.085 0.771
Error 1,166.876 114 10.236
Corrected total 1,345.293 117
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Health, the European Group on Tumor Markers, and the
European Society of Mastology, have recommended that
ER and PR be assayed on all primary breast cancers
because of the striking differences between the responses
of steroid receptor–positive and –negative breast cancers to
hormone therapy (3). Also, in advanced breast cancer the
state of tumors with regard to ER and PR is of great
importance before adjuvant endocrine treatment is initiated.
(20). C-erbB-2R is a member of subclass 1 of the superfamily
of receptor tyrosine kinases. Overexpression of C-erbB-2R
is associated with increased mitogenesis, malignant trans-
formation, cell motility, invasiveness, and metastasis and
appears to predict a poor response to tamoxifen and other
hormone therapies (3,21,22). However, C-erbB-2R is a re-
cently introduced predictive marker for selecting patients
with advanced breast cancer for treatment with therapeutic
antibodies such as trastuzumab (3). In addition, C-erbB-
2R1 tumors may indicate an enhanced sensitivity to high-
dose anthracycline-based regimens (3). Overexpression of
C-erbB-2R has also been suggested as an independent
prognostic indicator in patients with breast cancer (23,24).
Although 18F-FDG PET has been shown to provide
useful information in most patients with breast cancer
(25), reports describe some limitations of this methodology
(7,11,26). Breast carcinomas vary considerably in 18F-FDG
uptake (4–10). Therefore, based on the literature reports,
the appropriate role of 18F-FDG PET in assessing primary
lesions is unclear (26). The reasons for variability in
sensitivity have also been investigated by several studies.
Some investigated whether correlations exist between the
degree of 18F-FDG uptake and the receptor state of the
tumor that could predict tumor response to therapy and
forecast prognosis (9,12–15). Crowe et al. (15) investigated
the correlation between preoperative 18F-FDG uptake by a
tumor and the postoperative ER and PR states of the tumor
in 28 patients. Other groups have reported interesting
results in 32 patients (13), in 86 patients (9), in 56 patients
(12), and in 75 patients (14). However, no correlation has
been reported between the degree of 18F-FDG uptake and
TABLE 3
SUVmax Means in Different States of C-erbB-2R and ER
ER
Negative Positive
C-erbB-2R n SUVmax SE n SUVmax SE
Negative 23 6.63 1.10 73 2.77 0.23
Positive 13 3.90 0.62 7 6.01 1.60
FIGURE 1. (A) Graphic presentation of SUVmax means in
different combinations of ER and PR states shows no interac-
tion between ER and PR states, indicating that effects of ER
and PR states on 18F-FDG uptake were independent of each
other. (B) Graphic presentation of SUVmax means in different
combinations of ER and C-erbB-2R states shows that for
lesions in which both these receptors are either positive or
negative, SUVmax is higher than for lesions in which only one is
positive. (C) Graphic presentation of SUVmax means in different
combinations of C-erbB-2R and PR states shows that for
lesions in which both these receptors are either positive or
negative, SUVmax is higher than for lesions in which only one is
positive.
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the ER or PR content of the lesions in these studies (26).
In our study, we were able to detect for, what is to our
knowledge, the first time a correlation between ER state
and 18F-FDG uptake in tumors (Fig. 2). Also, instead of
using the mean SUV of the lesion, which is operator-
dependent, in this study we decided to use the SUVmax of
18F-FDG uptake as a reliable indicator of disease activity.
For the final analyses, we used only SUVmax. According to
our results, ER state alone had a significant effect on 18F-
FDG uptake in this malignancy. ER2 lesions had a signif-
icantly higher SUVmax than did ER1 lesions (5.64 6 0.75
vs. 3.03 6 0.26). However, neither PR state nor C-erbB-2R
state alone had an effect on 18F-FDG uptake. Only 1 study
in the literature (14) has attempted to determine the rela-
tionship between C-erbB-2R state and preoperative 18F-
FDG uptake by breast cancer. Similar to our findings, no
correlation was found between 18F-FDG uptake and the
C-erbB-2R state of the tumor. In this study, C-erbB-2R
expression was detected in 14 patients with invasive ductal
cancer, whereas no patient with lobular cancer showed
immunoreactivity to C-erbB-2R. In our study, all 20
C-erbB-2R1 lesions were of the invasive ductal type.
Therefore, our results were similar to those reported by
this group (14).
According to our results, there is an association between
ER and PR. The presence of one will likely accompany
that of the other in these tumors. There is also a reverse
association between ER and C-erbB-2R indicating that if
ER is positive, C-erbB-2R will likely be negative in the
malignant tissue. No association was noted between the PR
and C-erbB-2R states of these tumors.
We also investigated the interactions among receptor
states and the effects of such a biologic association on
18F-FDG uptake in this cancer. The interactions among
C-erbB-2R and ER or PR revealed that the presence or
absence of C-erB-2R reverses the effects of either PR or ER
on SUVmax measurements. However, such an interaction
was detected between ER and PR states, indicating that the
effects of these receptors on 18F-FDG uptake were inde-
pendent of each other. Despite the fact that many pathways
and cross-talks among these receptors are still incompletely
understood, we hope that the knowledge gained about their
effects on 18F-FDG uptake may allow for characterizing the
degree of aggressiveness of the tumor. In this prospective
study, we were able to show that ER2 tumors have a
significantly higher SUVmax than do tumors with positive
receptors. This finding would suggest that in these poorly
differentiated and aggressive tumors, glucose metabolism is
accelerated to meet the energy demand for rapid growth.
Another important finding of our study was that 25 lesions
larger than 5 mm on surgical specimens and with no 18F-
FDG uptake were ER1 whereas 18 were PR1 and only
1 was C-erbB-2R1. We excluded these from the initial
analysis, but if we were to include this population our
TABLE 5
SUVmax Means in Different States of C-erbB-2R and PR
PR
Negative Positive
C-erbB-2R n SUVmax SE n SUVmax SE
Negative 31 5.47 0.87 65 2.85 0.25
Positive 11 3.23 0.52 9 6.34 1.24
TABLE 4
ANOVA Table of ER and C-erbB-2R Effects on SUVmax
Source
Sum of
squares df
Mean
square F P
ER 10.934 1 10.934 1.175 0.281
C-erbB-2R 0.900 1 0.900 0.097 0.756
ER · C-erbB-2R 129.299 1 129.299 13.895 0.000
Error 1,042.215 112 9.305
Corrected total 1,338.120 115
TABLE 6
ANOVA Table of PR and C-erbB-2R Effects on SUVmax
Source
Sum of
squares df
Mean
square F P
PR 0.959 1 0.959 0.095 0.759
C-erbB-2R 6.334 1 6.334 0.627 0.430
PR · C-erbB-2R 131.359 1 131.359 12.999 0.000
Error 1,131.834 112 10.106
Corrected total 1,338.120 115
FIGURE 2. 18F-FDG PET images of 2 newly diagnosed breast
cancer patients who underwent preoperative PET studies. (A)
Image for which measured SUVmax of right breast lesion was
2.1 (arrow). After mastectomy, surgical pathology confirmed
1.2-cm invasive ductal cancer. Tissue receptor analysis
revealed that this lesion was ER1, PR1, and C-erbB-2R2.
(B) Image for which measured SUVmax of left breast lesion was
9.0 (arrow). After mastectomy, surgical pathology confirmed
2-cm invasive ductal cancer that was negative for ER, PR, and
C-erbB-2R. ER1 lesion showed significantly lower SUVmax
than did ER2 lesion.
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results would be quite striking, supporting our hypothesis
that poorly differentiated lesions are expected to be 18F-
FDG–avid in most settings. Clinical studies on gliomas and
lymphomas have also demonstrated that hypermetabolic
tumors are more aggressive than tumors with low metabolic
rates and that 18F-FDG PET can be used as a prognostic
indicator in these malignancies (27).
It was reported that the prognosis of breast cancer may
be determined on the basis of 18F-FDG PET results (28).
The state of various receptors in malignant breast tumors is
a major determinant of prognosis and an important step in
the initial work-up of breast carcinoma (29–32). Increased
fluoroestradiol activity in advanced tumors predicts a favor-
able prognosis and a probability of response to tamoxifen
(33). The premise of this study is to determine whether such
characteristics with regard to tumor activity would allow
the response to therapy to be forecast.
This study had limitations that possibly influenced the
findings. First, all patients had prior diagnostic core biopsies
that removed a portion of the cancer tissue. As a conse-
quence, the overall amount of 18F-FDG uptake was reduced,
resulting in lowering of the overall contrast of the lesion on
PET because of the partial-volume effect. On the other hand,
it is possible that in some patients an inflammatory reaction
after surgical intervention could have contributed to the
measured uptake in the lesion site. Considering the design of
the study, this type of effect was unavoidable but likely did
not substantially alter the results described. In addition, we
excluded patients who could have been inappropriate for this
analyses because of these factors.
CONCLUSION
SUV measurements may provide valuable information
about the state of ER, PR, and C- erbB-2R of primary
breast cancer lesions. Based on the data described here,
ER2 lesions have a significantly higher SUVmax than do
ER1 lesions. The results clearly demonstrated interactions
that affect the degree of 18F-FDG uptake (expressed as
SUV) of breast cancer lesions. Also, the C-erbB-2R state
interacts both with ER and with PR with regard to 18F-FDG
uptake. 18F-FDG PET is well known as a noninvasive
metabolic parameter for assessing the biologic aggressive-
ness of breast cancer, as our results substantiate. The
implications of the interactions among receptors and be-
tween the degree of 18F-FDG uptake and the receptor state
need to be investigated in future studies.
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